SCHEDULE: Wasatch Advisors LP Discloses 6.1% Stake in Esperion Therapeutics

Wasatch Advisors LP has reported beneficial ownership of 15,768,897 shares, representing 6.1% of the outstanding common stock of Esperion Therapeutics Inc.

Summary

• Wasatch Advisors LP has filed a Schedule 13G, indicating their beneficial ownership of Esperion Therapeutics Inc. common stock.
• The filing shows that Wasatch Advisors LP beneficially owns 15,768,897 shares of Esperion Therapeutics Inc. common stock.
• This ownership stake represents 6.1% of the total class of securities.
• The filing was made on April 22, 2026, with the event date being March 31, 2026.
• Wasatch Advisors LP holds sole power to dispose of all 15,768,897 shares and sole voting power over 12,377,523 of these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a known investment firm, but provides no operational or financial updates from the company itself.

Positives

• Wasatch Advisors LP, an investment adviser, has taken a significant stake in Esperion Therapeutics, potentially signaling confidence in the company's future prospects.
• The firm holds sole dispositive power over the entire stake, indicating clear control over these shares.
• A substantial portion of the shares (12,377,523) are held with sole voting power, suggesting active management and decision-making regarding these holdings.

Future Outlook

This filing does not contain forward-looking statements or guidance from Esperion Therapeutics Inc. It solely reports on the beneficial ownership of Wasatch Advisors LP.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by institutional investors like Wasatch Advisors LP can often be interpreted as a positive signal to the market, suggesting a belief in the company's underlying value or growth potential within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: The increased institutional ownership may be viewed positively, potentially leading to greater market interest and stability.
• Management: The filing confirms a significant investor's presence, which could influence strategic discussions.
• Creditors: No direct impact is indicated by this filing.

Key Dates

Recommendation

This filing is a Schedule 13G, which reports beneficial ownership by an institutional investor. While the acquisition of a 6.1% stake by Wasatch Advisors LP is a positive signal of institutional confidence, the filing itself does not provide any operational, financial, or strategic updates from Esperion Therapeutics. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions pending further company-specific news.

Keywords

Esperion Therapeutics, Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Adviser, Common Stock, Shareholder